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A survey was performed on the results of 138 carcinogenkicty studies conducted in various
mouse strins by the agrochemical industry over the period 1983-1993. Data for liver tumor
incidence, liver weight, and histopathology were collected along with data on genotoxicity.
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Carcinogenicity studies are performed in am-
mals to evaluate the risk oflong-term expo-
sure to chemicals for humans. The assump-
tion made from the start ofthe toxicological
evaluation process is that the effects found are
relevant to humans in the absence ofa com-
pelling argument to the contrary. Over the
years, organizations such as the National
Toxicology Program (NTP) have assembled
large databases on carcinogenicity testing
which reveal that carcinogenicity studies run
in rats are not necessarily predictive ofthe
result ofsimilar studies run in mice (1-3).
Available databases suggest that about 70% of
mouse carcnogens are positive in the rat and
70 to 75% ofrat carcinogens are positive in
the mouse (2,33. Whilethis situation is consis-
tent with the concept ofensuring that critical
effects are not missed, it also provides for the
possibility that some ofthe effects seen in one
species are notnecessarilyrelevantforanother.
Three otherfindings are dearfrom exam-
ination of such databases: 1) some tumor
types are more common in rats than in mice
andviceversa; 2) manycompounds produce
only one tumor type in one ofthe two test
species; and 3) many compounds produce
tumors onlyat thehighestdose tested.
In many respects these databases must be
suspected ofbeing misleading about the uni-
verseofchemicals. Compoundsselectedwere
not chosen at random, but were selected
according to various criteria, one ofwhich
was suspicion of carcinogenicity (1,4). For
this reason alone, it would be interesting to
look at a group ofchemicals that are highly
varied in structure, having in common only
that they are biologically active in some way
that makes them useful in agriculture. In
principle, such compounds can be assumed
to be free of any convincing evidence of
genotoxic activity, at least at the time they
were developed. Therefore, for the majority
of cases in which agrochemicals show posi-
tive results in carcinogenicity testing, they
canbeconsidered nongenotoxic carcinogens.
Liver tumors in mice show up as the
sole evidence of carcinogenicity so often
that their significance to humans has often
been debated (5-8). This is so much so that
current European Union (EU) legislation
considers that if the sole evidence comes
from liver tumors in "certain sensitive
strains of mice," that this should not be
regarded as evidence of carcinogenicity.
Unfortunately it is not stated which strains
ofmice should be considered sensitive.
This study performed by the European
Crop Protection Association (ECPA), with
assistance from the North American Crop
Protection Association (NACA), has
attempted to address the issues raised here.
What is the role oftoxicity in liver tumorige-
nesis in mice? Which strains appear more
sensitive? Is there a strong correlation
between liver weight increases and the
induction ofliver tumors? And finally, after
analyzing these data, underwhich conditions
should the finding ofmouse liver tumors be
considered as predictive ofcarcinogenicity in
humans either in the liver or in other organs?
Methods
Organization. The European Crop
Protection Association is an organization
representing the major agrochemical com-
panies doing business in Europe. The fol-
lowing companies contributed data to this
survey: Agrevo, Bayer, Ciba, Dow-Elanco,
Dupont, Monsanto, Rhone-Poulenc,
Sandoz, Uniroyal, and Zeneca.
Database. Participating companies were
asked to complete a questionnaire on all
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mouse carcinogenicity studies conducted
between January 1983 and January 1993.
Data required were: 1) year of study; 2)
duration of study (months); 3) strain of
mouse; 4) doses as percentages of the top
dose; 5) percentage survival by dose/sex
group; 6) percent tumor incidence for hepa-
tocellular adenoma, hepatocellular carcino-
ma, and other liver tumors; 7) dose/sex
group mean body weight after 6 months; 8)
dose/sex group mean relative liver weight at
1 year and/or at termination; 9) genotoxici-
ty; and 10) histopathological findings in liver
after 1 or 2 years according to the following
scale: indistinguishable from control, slight
but significant hypertrophy, more severe
hypertrophy with or without fatty vacuola-
tion, and severe degenerative changes.
A few submitted studies had to be
rejected because the duration was less than
18 months or the study was outside the
specified time range.
The assessment focused on the model,
i.e., on liver tumor formation in mouse
carcinogenicity studies, and was performed
blind with respect to compound identity.
Further, information was neither available
on possible oncogenic effects in other
organs nor on possible oncogenic effects in
corresponding rat carcinogenicity studies.
Treatment ofdata. For control data,
analyses ofvariance using duration ofstudy,
sex, and strain as independent variables were
used to assess the importance ofthese factors
on each ofthe quantitative endpoints request-
ed in the survey. Separate analyses ofvariance
werecarried outforeachoftheendpoints.
In assessing the data from the treated
groups, the first step was to provide an
evaluation ofwhether a study was positive
or negative in terms of tumor profile.
Information on whether studies were con-
sidered positive bythe parent company was
not requested on the original data sheets.
Studies were judged to be positive or nega-
tive by a weight-of-evidence evaluation
according to the following hierarchy:
* High dose compared to control: The exis-
tence of a treatment-related effect was
considered possible from a more than
50% increase in response.
Table 1. Number of studies submitted by strain
and duration ofstudy
Strain
Alpk:AP(Swiss)
B6C3F1
CD-1
C57BL/1OJ
NMRI
SPFICR(JCL:ICR)
Tif:MAGf
Total
Duration (months)
<19 19-23 >23
0 0 1
0 0 21
38 13 16
2 0 8
2 20 9
0 2 0
1 0 5
43 35 60
* High dose and control compared to the
control range ofthe respective strain: Was
the control value near the lower or upper
boundary ofthis range? Was the high dose
group inside or outside the control range?
* Plausibility of dose response: Did the
tumor response at intermediate doses cast
doubt on the relationship or reinforce it?
* Trend in malignancy: If a study was con-
sidered borderline after steps 1-3, it was
regarded positive ifthere was a dose-related
trend towards a higher proportion of
malignant tumors or ifthe high dose group
showed a markedly higher proportion of
malignant tumors than all othergroups.
None ofthese differences or trends was
tested with statistics because the sample was
considered too heterogeneous for this to add
to the credibility ofthe results. For example,
tumor incidences in control groups are
known to be dependent not only on the
strain but also on the supplier and the labo-
ratorywhere the studywas performed.
Clearly negative and positive studies
were easily identified and the hierarchical
approach was applied only to decide the
borderline cases. The final decision should
be seen as an expert judgment, and no
attempt was made to ascertain whether this
decision was consistent with that of the
company supplying the data. As the identi-
ty of the compounds was unknown, no
bias from this source was possible.
The importance of duration of study,
sex, and strain on the proportion ofpositive
studies was assessed using a logistic regres-
sion with sex, strain, and duration as inde-
pendent variables.
For top dose effects, as defined in subse-
quent sections, the importance of body
weight, survival, relative liver weight, and
liver histopathology on the proportion of
positive studies was assessed using logistic
regression. Separate analyses were carried out
with each individual parameter as the inde-
pendent variable. Analyses for relative liver
weight and liver histpathology were also car-
ried outseparately forlowerdose groups.
All data were stored and analyzed using
the SAS software package (SAS Institute,
Cary, NC) (9).
Results
Survey Response
A total of 138 valid studies was received
from 10 companies. The number ofstudies
available for each strain, subdivided by dura-
tion, is summarized in Table 1. Seven strains
of mice were used in the reported studies,
although only four ofthese had 10 or more
studies available. These were the CD-1 (67
studies), NMRI (31 studies), B6C3F1 (21
studies), and C57Bl/10J (10 studies).
Alpk:AP(Swiss), SPFICRJCL:ICR), and
TIF:MAGf mice were used in 1, 2, and 6
reported studies, respectively.
The studies ranged in duration from 18
to 27 months, but for the purposes of this
report they were classified into three groups
Table 2. Control summary data
Sex
Males
Females
Total per
strain
21
67
10
31
2
6
138
Duration
[months) Strain
<19 CD-1
C57BL/1OJ
NMRI
Tif:MAGf
19-23 CD-1
NMRI
SPFICR(JCL:ICR)
>23 Alpk:AP(Swiss)
B6C3F1
CD-1
C57BL/1OJ
NMRI
Tif:MAGf
<19 CD-1
C57BL/1OJ
NMRI
Tif:MAGf
19-23 CD-1
NMRI
SPFICR(JCL:ICR)
>23 Alpk:AP(Swiss)
B6C3F1
CD-1
C57BL/1OJ
NMRI
Tif:MAGf
Survival
(%)
60.9
84.0
78.0
84.0
48.8
64.4
26.8
33.0
84.0
40.2
54.2
56.7
45.8
66.1
78.0
73.0
90.0
50.0
43.2
32.8
27.0
77.3
44.3
53.0
41.7
45.5
Bodyweight
(g)
41.2
31.3
48.0
44.3
40.4
44.4
48.6
48.0
33.3
40.2
32.2
41.2
49.9
32.6
24.9
34.5
35.3
31.2
32.8
43.8
41.2
28.3
33.3
25.5
31.7
42.3
Incidence of livertumors
Hepatocellular Hepatocellular
adenomas(%) carcinomas(%)
10.3 5.0
1.0 1.0
14.0 7.0
12.0 0.0
9.7 7.8
5.0 4.1
4.6 3.5
10.0 30.0
15.4 15.6
14.3 10.4
1.1 0.5
4.0 1.2
28.0 12.1
0.9 0.5
1.0 0.0
4.0 1.0
1.7 1.7
2.3 1.1
1.2 1.2
0.8 0.6
2.0 2.0
8.5 3.9
3.2 1.0
0.3 0.0
0.9 0.8
9.0 4.4
Other
(%)
2.5
0.0
0.0
1.7
3.5
1.6
0.8
18.0
1.2
3.9
10.8
5.0
10.1
2.7
0.0
0.0
0.0
6.8
0.8
0.8
10.0
0.4
3.6
3.6
2.1
15.6
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Table 3. Cross-reference of carcinogenic response
in males andfemales
Positive Negative Total
in males in males (females)
Positive in females 16 5 21
Negative in females 16 101 117
Total (males) 32 106 138
Table4. Carcinogenic response bysex and duration
ofstudy
Duration Proportion of positive studies
(months) Males Females
<19 9/43 (21%) 8/42 (19%)
19-23 6/35 (17%) 4/34(12%)
>23 17/60(28%) 9/62(15%)
Total 32/138(23%) 21/138(15%)
Table 5. Carcinogenic response bystrain
Proportion of positive studies
Strain Males Females
Alpk:AP (Swiss) 0/1 (0%) 0/1 (0%)
B6C3F1 4/21 (19%) 4/21 (19%)
CD-1 13/67 (19%) 10/67(15%)
C57BL/10J 5/10(50%) 1/10(10%)
NMRI 6/31 (19%) 4/31 (13%)
SPFICR (JCL:ICR) 1/2(50%) 1/2(50%)
Tif:MAGf 3/6(50%) 1/6(17%)
approximating 18, 21, and 24 month stud-
ies, i.e., studies <19 months, 19-23 months,
and >23 months, respectively. Studies ofless
than 19 months duration used primarily
CD-1 mice (total 38 out of45). Studies of
19-23 months in duration used primarily
NMRI or CD-1 mice (total 33 of35), and
B6C3F1 or CD-1 strains were the most
common strains in the studies of longer
duration (total 37 of60).
Control Group Data
Table 2 contains a summary ofsurvival at
study termination, absolute bodyweight at
6 months, and tumor incidence for the
control groups for each study duration,
split by sex and strain ofmouse. The most
important findings are listed below.
There were clear statistically significant
(p<O.O1) differences in the survival rates for
the control groups in the different strains.
The B6C3F1 had very good survival to 2
years (about 80%), whereas the other
strains averaged approximately 40-55% at
2 years. There were no conclusive differ-
ences in survival patterns between the
sexes. Not surprisingly, survival was lower
as the duration increased.
There were dear statistically significant
(p<0.01) differences in absolute body
weights at 6 months for the different strains,
which were independent ofstudy duration
and sex. The C57BI/1OJ and B6C3F1 mice
tended to be smaller; the Alpk:AP(Swiss),
Table 6.Top dose bodyweight effects
Carcinogenic Percent bodyweight reduction at6 months
Sex response >10% (n) 5-10% (n) 0-5% (n) Increase (n)
Male Positive 16(5) 34(11) 34(11) 16(5)
Negative 13 (14) 32(34) 36(38) 19(20)
Total males 14 (19) 33(45) 36(49) 18(25)
Female Positive 11(2) 26(5) 47(9) 16 (3)
Negative 5(6) 18(21) 38(45) 38(45)
Total females 6(8) 19(26) 40(54) 35(48)
Worst-affected sex Overall 14(20) 35(48) 38(52) 13(18)
Table 7. Top dose survival effects
Carcinogenic Percentsurvival reduction
Sex response >10% (n) 5-10% (n) 0-5% (n) Increase (n)
Male Positive 19 (6) 0 (0) 0(0) 81(26)
Negative 19 (20) 9(10) 16(17) 56(59)
Total males 19(26) 7 (10) 12(17) 62(85)
Female Positive 16 (3) 11(2) 5(1) 68(13)
Negative 14(16) 14(16) 17(20) 56(65)
Total females 14(19) 13(18) 15(21) 57(78)
Worst-affected sex Overall 25(34) 17 (24) 13(18) 45(62)
Tif:Magf, and SPFICR JCL:ICR) mice
were larger; and the bodyweights ofNMRI
and CD-I mice were intermediate.
For hepatocellular adenomas and carci-
nomas, the incidence in males was generally
higher than that seen in females. The inci-
dence ofthese tumors in theC57BI/1OJ mice
was very low, the highest incidences being
seen in TifMagf, B6C3F1, Alpk: AP(Swiss),
and CD-1 mice. There was no conclusive
evidence for an increase in tumor incidence
withstudyduration in thosestrains forwhich
this comparison couldbemade.
Other liver tumors were clearly more
prevalent in studies >23 months in duration
than in shorter-term studies. Their incidence
was particularly high for the Tif:Magf,
C57BI/1OJ, and male Alpk: AP(Swiss) mice.
Because these tumor types were not usually
further identified in the survey forms, they
were notanalyzedfurther.
Treated Group Data
Classification oftumorigenicizy. Ofthe 138
studies reported, 101 werejudged to benega-
tive in terms oftumorigenicity in both sexes,
and 16 were positive in both sexes (Table 3).
Ofthe remaining 21 positive studies, 16were
positive in males only and 5 were positive in
females only. Although the incidence ofposi-
tive studies was higher in males than in
females, this difference was insufficient to
attain statisticalsignificance (p = 0.09).
Theproportionofpositivestudieswas not
affected by either the duration of the study
(Table4) orthestrainofmouse (Table 5).
Genotoxicity. Only 8 of the chemicals
tested in the 138 studies showed positive
Ames tests. Ofthese 8 studies, 7 were con-
sidered negative for tumors in both sexes and
1 was positive for tumors in males only.
Of the 37 studies judged positive for
tumors, only 1 wasAmes positive and only6
showed a positive result in any genotoxic
assay (predominantlychromosomal in vitro).
Survival effects. Survival effects were
calculated as the top dose group percentage
survival minus the control group percent-
age survival. Top dose survival effects are
summarized in Table 6.
No conclusive difference was seen in
the survival effects between the sexes. A
small but statistically significant (p = 0.02)
association was seen between tumorigenic
response and reduced survival for males
only. On the basis of survival and body
weight as described below, however, there
was no evidence of excessive toxicity as a
confounding effect in the overall database.
Body weighteffects. Bodyweight effects
were calculated as the difference in
absolute bodyweight at 6 months between
the top dose group and the control group,
expressed as a percentage of the control
group body weight. Top dose body weight
effects are summarized in Table 7.
Abodyweight reduction in excess of10%
was seen in 14% ofthestudies, with atotal of
49% showing an effect in excess of 5%. No
topdosereduction inbodyweightwas seen in
13% ofstudies. Top dosebodyweight reduc-
tions were statistically significantly (p<0.01)
greater inmales than infemales.
The information at 6 months can only
provide a snapshot of the actual body
weight effect achieved, in that different
effects could have been observed earlier or
later in a study. Also, examination ofbody
weight gain would have given a greater per-
centage difference, but this could not be cal-
culated from the information requested in
the survey. However, it would appear that
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Figure 1. Liver histopathology after treatment for 1 year. (A) Positive studies in males. (B) Negative studies in males. (C) Positive studies in females. (D) Negative
studies in females. Abbreviations: LOW, low dose; MID1, lower medium dose; MID2, higher medium dose; TOP, top dose; -, indistinguishable from control; +, slight
butsignificant hypertrophy; ++, more severe hypertrophy with orwithoutfattyvacuolation; +++, severe degenerative changes.
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Figure 2. Liver histopathology after treatment for 2 years. (A) Positive studies in males. (B) Negative studies in males. (C) Positive studies in females. (D) Negative
studies in females. LOW, low dose; MID1, lower medium dose; MID2, higher medium dose; TOP, top dose; -, indistinguishable from control; +, slight but significant
hypertrophy; ++, more severe hypertrophy with or withoutfatty vacuolation; +++, severe degenerative changes.
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approximately half the studies examined
had insufficient reductions in body weight
tojustify a maximum tolerated dose (MTD)
on the basis of body weight alone. There
was, however, no conclusive evidence for an
association between the body weight effect
achieved and the carcinogenic response.
Liver histopathology. Figures 1 and 2
show the relationship between tumorigenic
response and liver histopathology findings
for males and females at 1 and 2 years,
respectively. A clear statistically significant
(p<0.01) association is present for both
sexes at both 1 and 2 years at the top dose.
This was also present for the highest mid-
dle doses in both sexes at 2 years and in
males only at 1 year.
Histopathological findings were clearly
more severe in positive studies than in neg-
ative studies. Indeed, the vast majority of
findings of more severe hypertrophy with
or without fatty vacuolation and severe
degenerative changes were seen in positive
studies. It was usual to see no histopatho-
logical effects at the low dose. These find-
ings were present at 1 and 2 years, despite
the increased background histopathology
likely to be present at 2 years.
Relative liver weight. Relative liver
weight effects were calculated as the treated
group mean expressed as a percentage of
the control group mean. Figures 3 and 4
show the relationship between the tumori-
genic response and the relative liver weight
effect at 1 and 2 years, respectively, by sex
and dose level. A statistically significant
association (p<0.01) was seen between
tumorigenic response and increased relative
liver weight at 1 and 2 years in both sexes
at the top dose. This was also seen at the
highest middle doses for both sexes at 1
and 2 years (p<0.05).
Relative liver weight effects were clearly
greater in positive studies than in negative
studies. Indeed, an increased relative liver
weight of less than 20% at 1 year would
appear to be highly predictive ofa negative
tumor response at 2 years. Relative liver
weights at the low dose were generally
unaffected. The findings at 1 and 2 years
were consistent, although the 2-year data is
subject to more uncertainty owing to the
possible inclusion or exclusion of tumor
bearing animals from the reported results.
Discussion and Conclusions
More than half of the chemicals tested to
date in chronic rodent bioassays have been
found to be tumorigenic in both rats and
mice at the high doses administered. Even
though the majority, in amount and num-
ber, ofthe chemicals to which humans are
exposed are natural, only 77 out of 427
chemicals tested in rats and mice before
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Figure 3. Relative liverweights aftertreatmentfor
1 year. Abbreviations: LOW; low dose; MID1,
lower medium dose; MID2, higher medium dose;
TOP,top dose.
1990 were natural. Surprisingly, about half
ofthese natural chemicals (37/77; 48%) are
rodent carcinogens, approximately the same
proportion as synthetic industrial chemicals
from which 212/350 (61%) were classified
as rodent carcinogens [see Ames and Gold
(10) and references cited therein]. The high
number ofpositives is not simply the result
ofselective testing because ofapnorisuspi-
cion of mutagenicity and carcinogenicity.
Many chemicals were selected because they
were high-volume chemicals and were
widely used in industry, crop protection, or
food technology.
The liver is the most frequent site of
carcinogenicity in both rats and mice in
these experiments (11,12). This fact is illus-
trated in a recent review (11) of299 mouse
tumorigens in a large database, from which
171 (57%) induced tumors in the liver in
mice, and of 354 rat tumorigens, from
which 143 (40%) induced tumors in the
liver in rats. In the current survey, about
27% of the mouse bioassays reported were
judged to be positive in terms ofhepatocel-
lular tumorigenicity. This does not neces-
sarily mean that they were considered posi-
tive by the company submitting the data or
by regulators, and the same is true for nega-
tive studies. The percentage of positive
studies in the current survey is lower than
that reported in the review (11), which may
be due to the fact that the compounds were
selected to be developed after excluding
compounds with alerts for carcinogenicity.
It could also be due to a different threshold
for judging a study positive. In our
approach, positive or negative carcinogenic-
ity was judged by an examination of the
study on its own and against the control
data ofother studies in the same strain, not
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Figure 4. Relative liverweights after treatmentfor
2 years. Abbreviations: LOW, low dose; MID1,
lower medium dose; MID2, higher medium dose;
TOP, top dose.
by statistics. Nevertheless, a significant pro-
portion ofthe compounds tested were liver
tumorigens, and this requires consideration
ofthe mechanisms underlying spontaneous
and chemically induced expression of
mouse liver tumors and its likely signifi-
cance for humans.
Spontaneous formation ofhepatocellu-
lar neoplasms in mice and rats may differ
because spontaneous liver tumors are rela-
tively rare in most strains of rats (13) but
are frequent in many strains of mice. The
historical control incidence for liver tumors
in the NTP studies was 35% for male
B6C3F1 mice and 13% for females, while
it was 3% for male F344 rats and 1% for
female F344 rats, indicating not only
species but also sex differences with regard
to spontaneous liver tumors (14). The exis-
tence of sex differences in spontaneous
rates and in sensitivity to chemically
induced tumors was confirmed in this
study, although the difference in sensitivity
was not dramatic.
Interspecies comparisons between rats
and mice of liver-specific tumorigenic
effects revealed that a chemical tumori-
genic to the liver of male and/or female
rats was four times more likely to be a
mouse liver carcinogen than was a chemi-
cal not carcinogenic to rat liver (76% vs.
19%) (12). On the other hand, there
appears to be no particular tendency for
mouse liver tumors to predict rat liver
tumors (15). These observations suggest a
significantlyhigher sensitivity ofthe mouse
liver towards tumorigenic effects and may
question the predictivity of mouse liver
tumorigenicity data for such effects in the
rat. The predictivity is probably even less
for humans, for which chemically induced
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hepatocellular tumors have been described
as rare events (16,17).
In addition, major interstrain differences
exist among mice. The C3H/HeN mouse,
for example, is known to exhibit extremely
high (up to 100%) incidence, whereas the
C57BL/6N and BALB/cA strains are char-
acterized by a very low (<1 %) frequency of
spontaneous hepatomas (18). These large
strain differences in spontaneous rates were
confirmed, but we did not find evidence of
any striking difference in sensitivity between
strains based on the criteria we used to
judge positive studies.
Among the 37 studies judged to be
positive for mouse liver tumor formation
in this survey, only one was Ames positive.
This means that nearly all positive results
were obtained with compounds which are
likely to induce liver tumors by nongeno-
toxic mechanisms. The analysis ofour data
has demonstrated a strong association
between the outcome of positive tumori-
genicity and increased liver weight at 1
year. Top dose liver weights in positive
studies averaged 150% of control values,
whereas negative studies were at about
1 0%. [Strongly increased liver weights as
a biological response might provide a good
indication that a sufficient dose was
administered. As an alternative to MTD
values based on reduced body weights, one
might interpret a dose level that causes a
strong increase in the (relative) liver weight
as sufficient to represent an MTD.]
Likewise the association between posi-
tive histopathological findings (hypertro-
phy and/or degenerative changes) and liver
tumor formation was equally strong. Very
few negative studies had any positive find-
ings in the 52-week histopathology, where-
as the majority of positive studies had at
least minor pathological changes. These
findings, while not implying a common
mechanism, suggest that for the investigat-
ed nongenotoxic compounds the features
of hepatomegaly and/or histopathological
changes at 1 year are predictive ofa signifi-
cantly increased chance to observe liver
tumors at the final sacrifice.
Various hypotheses exist on the mecha-
nisms by which nongenotoxic hepatocar-
cinogens induce hepatomegaly and/or
histopathological changes, and finally
tumor formation (19-21). Upon subchron-
ic administration, many of these com-
pounds either stimulate hepatocyte cell pro-
liferation and/or act as liver enzyme induc-
ers. Compounds that act as liver mitogens
directly exhibit a proliferative stimulus on
hepatocytes. Alternatively, compounds that
are cytotoxic to hepatocytes stimulate cell
proliferation indirectly, whereby this com-
pensatory hyperplasia is regarded as a
regenerative process in response to sus-
tained cytotoxicity. Liver enzyme induction
can be observed with many compounds
upon short-term treatment and is interpret-
ed as an adaptive, reversible response ofthe
organ to a functional load. The increased
incidences ofliver tumors, as observed with
such compounds upon long-term treatment
of laboratory rodents, are generally con-
fined to high dose levels at which the com-
pounds interfere with normal liver home-
ostasis, i.e., act as mitogens, cytotoxicants,
or enzyme inducers.
The effects caused by these nongeno-
toxic compounds do not imply a direct
interaction with DNA and are therefore
likely to be threshold related, i.e., dose lev-
els exist at or below the level at which no
response will take place (20,21). If pro-
longed disturbance of organ function is a
prerequisite of a positive outcome in the
majority of studies, it casts considerable
doubt on the potential to extrapolate these
findings to lower levels of exposure where
hepatomegaly or liver toxicity are absent.
Consequently, these high dose phenomena
are unlikely to occur under conditions of
human exposure.
Additional mechanistic features specific
to the mouse may support the view that
tumor formation in mice is related to liver
cell proliferation or enzyme induction and
may differ from humans. There is good
evidence for the existence ofa considerable
number of initiated or latent tumor cells
specifically in mouse liver. A promotional
effect of mouse liver carcinogens may be
characterized by a specific proliferation
stimulus on these cells specific for this
species (22-25). In addition, monooxyge-
nase activities in the mouse liver are gener-
ally higher than those in rats or humans;
among them are aryl hydrocarbon hydrox-
ylase and biphenyl 2-hydroxylase, two
activities mainly catalyzed by cytochrome
P450 isoenzymes of gene family CYPIA
(26-28). These isoenzymes are known to
be efficient in the production of reactive
intermediates, and their constitutive pres-
ence in mouse liver, albeit at low levels,
suggests a certain endogenous initiating
potential in this species, particularly affect-
ing unprotected replicating DNA under
conditions of increased mitogenic activity,
which would not occur in humans (26).
In considering the relevance of mouse
bioassays to human risk assessment, in
addition to the mechanism of liver tumor
formation in the mouse, risk factors rele-
vant for carcinogenesis in humans are to be
considered as well. Two questions are to be
answered: Can potential human carcino-
gens be identified by a mouse liver tumor
response? More specifically, can potential
human liver carcinogens be identified by a
mouse liver tumor response?
Benzidine provides an answer to the
first question. Like some other genotoxic
aromatic amines, benzidine is a bladder car-
cinogen in humans and induces liver
tumors in rodents. In this case, liver tumor
formation in mice and rats is obviously pre-
dictive for tumor formation in humans in
another organ, i.e., the bladder (29,30).
However, aromatic amines are genotoxic
carcinogens, and their main mode ofaction
is tumor initiation by covalent binding to
DNA following metabolic activation (31).
To our knowledge, there is no correspond-
ing example ofa nongenotoxic mouse liver
carcinogen that was identified as a carcino-
gen in humans in another organ.
The following discussion will therefore
concentrate on epidemiological data and
etiological considerations that may eluci-
date the differences between liver tumor-
inducing agents in rodents and humans.
Epidemiological evidence from the clin-
ical use ofhigh doses ofphenobarbitone, a
noncytotoxic stimulator of cell prolifera-
tion and inhibitor ofapoptosis as well as an
enzyme inducer in the rodent liver
(21,32,33), for more than 80 years indi-
cates neither increased incidences ofhepat-
ic cancer nor the formation of tumors at
any other site in humans (34). The main
risk factors for hepatocellular carcinomas
in humans are viral hepatitis, alcoholism,
and aflatoxin. In high incidence areas, viral
infection is the predominant risk factor,
whereas in the Western World alcohol is
the single most important risk factor
(35-37. Viral hepatitis has been proposed
to be responsible for 75-90% of all hepa-
tocellular carcinomas worldwide (38). For
high incidence areas, the combined effects
ofhepatitis, aflatoxin, and alcohol compli-
cate a risk calculation. Synergistic effects of
ethanol and hepatitis on liver cancer have
been observed in Japan (39-42) and urban
regions ofAfrica (43).
Although liver cirrhosis usually coexists
with hepatocellular carcinoma, some
patients with hepatitis B infection may
develop hepatocellular carcinomas that are
not superimposed on cirrhosis, indicating
that viral hepatitis may exert some direct
effect on hepatocarcinogenesis (37,44).
Hepatocellular carcinomas and cirrhosis
appear to share a common etiology, and
the likely culprit in the high incidence
areas is persistent infection with hepatitis B
virus (45). In contrast, in low incidence
areas, alcohol-related cirrhosis is probably
the most important cause ofhepatocellular
carcinoma (35).
Even in the absence ofcirrhosis, hepa-
tocellular carcinomas in humans usually do
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not occur in an otherwise histologically
normal liver. In an Italian study (46), more
than 140 cases ofhepatocellular carcinoma
were investigated, and all but one occurred
in patients with histologic evidence ofliver
cirrhosis. In a series of 618 hepatocellular
carcinomas in Japanese patients, 66 hepa-
tocellular carcinomas without cirrhosis but
only 3 cases (0.5%) without histological
findings like dysplasia and fibrosis in the
surrounding liver were found (47).
The impact of natural or man-made
chemicals on human hepatocellular carci-
noma epidemiology is doubtful or very
small (48). There were a few recent reports
ofan increased incidence ofliver tumors in
chemical workers (49-51) and in solvent-
exposed workers in the Nordic countries
(52,53). Epidemiological evidence for the
induction of hepatocellular carcinomas by
environmental pollution has not been
reported except for a few reports from
China. An association between hepatocel-
lular carcinomas and drinking of ditch
water was reported by several authors
(54-56); however, this association could
not be attributed to pesticides (55,57) and
is more likely virus related.
It can be seen that the vast majority of
liver tumors in humans can be attributed
to known causes mostly associated with
hepatitis and/or cirrhosis. In addition, the
mechanism of liver tumor genesis in mice
and humans appears to differ, casting
doubt on whether mouse carcinogenicity
studies are predictive of a potential car-
cinogenic effect in humans. Moreover,
there does not appear to be a correspond-
ing public health problem. This leads to
two alternative conclusions: the high pro-
portion of positive mouse (and, to a lesser
extent, rat) studies is an artifact of their
design and has very little relevance to man,
or the potential demonstrated by these
studies may be relevant to very high levels
ofexposure but not to trace quantities typ-
ical ofthe everyday environment.
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